Experimental Investigation of Hematological Toxicity After Radiation Therapy Combined With Immune Checkpoint Inhibitors
International Journal of Radiation Oncology*Biology*Physics · 2025-10 · 123 (2) · 523-535
DOI: 10.1016/j.ijrobp.2025.04.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025-10. Verfasst von Vincent R Timnik und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Else Kroner-Fresenius Foundation, Technische Universität München.
Abstract (Originalsprache)
PURPOSE: Combining immune checkpoint inhibitors (ICIs) with radiation therapy (RT) has led to significant advancements in cancer treatment. However, evidence from clinical and experimental studies suggests that this combination may increase hematopoietic and lymphatic toxicity. This study aims to investigate the effects of the concurrent application of ICIs (anti-PD-1 and anti-CTLA-4) on radiation-induced hematopoietic and lymphatic injuries under standardized and controlled experimental conditions. METHODS AND MATERIALS: We used various experimental models in C57BL/6 and BALB/c mice to evaluate the impact of ICIs combined with RT on the hematopoietic system. These models involved different RT doses, regimens, and target sites in both healthy and tumor-bearing mice. RESULTS: Our findings showed that the concurrent use of ICIs did not meaningfully affect post-RT pancytopenia kinetics or the regeneration of specific blood cell lineages over time. Consistently, combining RT with ICIs did not significantly enhance DNA damage in immune cells within the bloodstream. This outcome was comparable across different RT doses, regimens, and target sites and was reproducible in both tumor-bearing and nontumor-bearing mice. Additionally, there were no significant increases in late side effects, including reductions in bone marrow cell counts or megakaryocyte numbers, after combined radioimmunotherapy. CONCLUSIONS: These findings suggest that combining ICIs with RT does not exacerbate hematological toxicity. This information is valuable for interpreting adverse events in clinical trials involving radioimmunotherapy and for predicting potential hematological side effects in cancer patients receiving these treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Comparative Experimental Pathology (CEP), Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner-site Munich and German Cancer Research Cent…
- Department of Radiation Oncology, Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner-site Munich and German Cancer Rese…
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France; Metabolomics and Cell Biolo…
- Department of Radiation Oncology, Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany; Helmholtz Zentrum München, Institute of Radiation Medicine, Neuherberg, Ger…
- Department of Radiation Oncology, Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany; Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre l…
Förderung
- German Research Foundation
- Else Kroner-Fresenius Foundation
- Technische Universität München
- Faculty of Medicine, Munich University of Technology
- German Cancer Aid
Zitieren
APA
Timnik, V. R., Zoeschg, A., Diederich, S., Nefzger, S. M., Huang, Z., Schmid, N. A., Giller, M., Steiger, K., Combs, S. E., Kroemer, G., Schmid, T. E., & Fischer, J. C. (2025). Experimental Investigation of Hematological Toxicity After Radiation Therapy Combined With Immune Checkpoint Inhibitors. International Journal of Radiation Oncology*Biology*Physics, 123(2), 523-535. https://doi.org/10.1016/j.ijrobp.2025.04.008
Vancouver
Timnik VR, Zoeschg A, Diederich S, Nefzger SM, Huang Z, Schmid NA, et al. Experimental Investigation of Hematological Toxicity After Radiation Therapy Combined With Immune Checkpoint Inhibitors. International Journal of Radiation Oncology*Biology*Physics. 2025;123(2):523-535. doi:10.1016/j.ijrobp.2025.04.008
BibTeX
@article{Timnik2025,
author = {Timnik, Vincent R and Zoeschg, Andreas and Diederich, Sarah and Nefzger, Sophie M and Huang, Ziyi and Schmid, Nicole A and Giller, Maximilian and Steiger, Katja and Combs, Stephanie E and Kroemer, Guido and Schmid, Thomas E and Fischer, Julius C},
title = {Experimental Investigation of Hematological Toxicity After Radiation Therapy Combined With Immune Checkpoint Inhibitors},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
volume = {123},
number = {2},
pages = {523--535},
doi = {10.1016/j.ijrobp.2025.04.008}
}
EUVIMED